Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zevra TherapeuticsSTU:1GDA +0.82%69 Gross Margin % is 96.16% as of Jun. 2026, which is 7% above its 10-year median of 90.18. GuruFocus rates STU:1GDA with a GF Score™ of 69/100 and a GF Value™ of €17.92 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 735 Biotechnology companies, Zevra Therapeutics ranks better than 93.47% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Zevra Therapeutics had a gross margin of 96.16% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Zevra Therapeutics Gross Margin % Related Terms
Zevra Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Zevra Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1GDA vs TECX, RLMD, ALT: Gross Margin % Comparison
For the Biotechnology subindustry, Zevra Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zevra Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Zevra Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Zevra Therapeutics (STU:1GDA) has a Gross Margin % of 96.16% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Zevra Therapeutics and its competitors. This is near median its historical median of 90.18. Over the past decade, Zevra Therapeutics' Gross Margin % has ranged from 68.59 to 97.82. According to the industry distribution chart, Zevra Therapeutics ranks #48 out of 735 companies in the Biotechnology industry, placing it in the top 6.5%.
Is Zevra Therapeutics' Gross Margin % too high?
Zevra Therapeutics' current Gross Margin % of 96.16% is near median its 10-year median of 90.18. Over the past 10 years, this metric has ranged from a low of 68.59 to a high of 97.82. The Biotechnology industry median Gross Margin % is 60.91. Zevra Therapeutics' value of 96.16% is 57.9% above this industry median. Based on the distribution chart, Zevra Therapeutics ranks #48 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zevra Therapeutics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' Gross Margin % compare to TECX and RLMD?
According to the Biotechnology industry distribution chart, Zevra Therapeutics ranks #48 out of 735 companies for Gross Margin %. This places Zevra Therapeutics in the top 7% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Zevra Therapeutics' value of 96.16% is 57.9% above this benchmark. Historically, Zevra Therapeutics' own Gross Margin % has ranged from 68.59 to 97.82 over the past decade. While the company's 10-year median is 90.18 vs. the industry median of 60.91, Zevra Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zevra Therapeutics's current Gross Margin % of 96.16% is 57.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Zevra Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zevra Therapeutics's current Gross Margin % is 96.16%, which is near median its own 10-year median of 90.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (STU:1GDA) is currently considered Possible Value Trap. The stock's GF Value™ is €17.92, compared to a current price of €9.80 — trading 45.3% below its estimated fair value. The current Gross Margin % is 96.16%, which is near median its 10-year median of 90.18 and 57.9% above the Biotechnology industry median of 60.91. Zevra Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Zevra Therapeutics (STU:1GDA), the current Gross Margin % is 96.16% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zevra Therapeutics (STU:1GDA) Overvalued in 2026?
Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued.
The current stock price of €9.80 is trading 45.3% below its estimated GF Value™ of €17.92.
GuruFocus considers Zevra Therapeutics to be Possible Value Trap.
Key valuation signals for STU:1GDA:
Gross Margin %: 96.16% (near median its 10-year median of 90.18)
GF Value™: €17.92 vs. price of €9.80 (45.3% below fair value)
Industry Position: 57.9% above the Biotechnology median (#48 of 735)
No single metric tells the full story. See the STU:1GDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
69GF Score
Get the complete analysis for STU:1GDA
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1GDA has been successfully added to your 
